#innovation-policy

#innovation-policy

The U.S. Chamber of Commerce's Global Innovation Policy Center warns the USPTO against proposals for increased collaboration with the FDA, describing them as misguided 'coordination' efforts. These efforts are perceived as aimed at addressing perceived links between drug pricing and patent issues, which could complicate the patent examination process.